Core Viewpoint - Ipsen has voluntarily withdrawn Tazverik (tazemetostat) from all markets due to emerging safety concerns regarding secondary hematologic malignancies, as advised by the Independent Data Monitoring Committee (IDMC) [1][3] Group 1: Withdrawal Details - The withdrawal of Tazverik affects all indications, including follicular lymphoma (FL) and epithelioid sarcoma (ES), and is effective immediately [1] - Ipsen has initiated steps to stop treatment with tazemetostat for all patients currently enrolled in the SYMPHONY-1 trial, transitioning them to standard care with lenalidomide plus rituximab [2] - All active tazemetostat clinical trials and expanded access programs are being discontinued [2] Group 2: Clinical Trial Information - The SYMPHONY-1 trial is a global Phase Ib/III study evaluating Tazverik in combination with lenalidomide and rituximab as a second-line therapy for relapsed/refractory follicular lymphoma [7] - The trial spans 229 sites across 15 countries, including the U.S., EU, and China, and includes analyses for both EZH2-wild-type and EZH2-mutant patient populations [8] Group 3: Regulatory and Market Impact - Ipsen is collaborating with the U.S. Food and Drug Administration (FDA) to execute the withdrawal and provide necessary information [3] - Tazverik received accelerated approval from the FDA in 2020 for specific patient populations, including adults with relapsed or refractory FL and those with metastatic or locally advanced epithelioid sarcoma [3][5] - The withdrawal is not expected to impact the company's financial guidance [4]

Core Viewpoint - Ipsen has voluntarily withdrawn Tazverik (tazemetostat) from all markets due to emerging safety concerns related to secondary hematologic malignancies, as advised by the Independent Data Monitoring Committee (IDMC) [1][3] Withdrawal Details - The withdrawal of Tazverik affects all indications, including follicular lymphoma (FL) and epithelioid sarcoma (ES), and is effective immediately [1] - Ipsen has initiated steps to stop treatment with tazemetostat for all patients currently enrolled in the SYMPHONY-1 trial, transitioning them to standard care with lenalidomide plus rituximab [2] - All active tazemetostat clinical trials and expanded access programs are being discontinued [2] Clinical Trial Information - The SYMPHONY-1 trial is a global Phase Ib/III study evaluating Tazverik in combination with lenalidomide and rituximab as a second-line therapy for relapsed/refractory follicular lymphoma [7] - The trial spans 229 sites across 15 countries, including the U.S., EU, and China, and includes analyses for both EZH2-wild-type and EZH2-mutant patient populations [8] Regulatory and Market Impact - Ipsen is collaborating with the U.S. Food and Drug Administration (FDA) to execute the withdrawal and provide necessary information [3] - Tazverik received accelerated approval from the FDA in 2020 for specific patient populations, including adults with relapsed or refractory FL and those with metastatic or locally advanced epithelioid sarcoma [3][5] Financial Guidance - The withdrawal of Tazverik is not expected to impact the company's financial guidance [4]